Skip to main content

Table 2 Concomitant diagnoses and medications at 2006 and during follow-up

From: Cardiovascular disease in diffuse idiopathic skeletal hyperostosis (DISH): from theory to reality—a 10-year follow-up study

   DISH
N = 45 (%)
Control
N = 47 (%)
P value
Dyslipidemia 2006 N (%) (48.9) 22 (29.8) 14 0.06
2016 N (%) (81.1) 36 (69.6) 32 0.176
HTN 2006 N (%) (62.2) 28 (38.3) 18 0.02
2016 N (%) (86.7) 39 (59.6) 28 0.003
Type 2 DM 2006 N (%) (33.3) 15 (8.5) 4 0.003
2016 N (%) (59.1) 26 (17) 8 < 0.0001
Heart failure (HFrEF + HFpEF) 2006 N (%) 0 (0) 0 (0)  
2016 N (%) 13 (28.9) 12 (25.5) 0.717
Aspirin treatment 2006 N (%) (35.6) 16 (19.2) 9 0.077
2016 N (%) (60) 27 (44.7) 21 0.598
ACEi/ARB treatment 2006 N (%) (31.1) 14 (14.9) 7 0.063
2016 N (%) (62.2) 28 (27.7) 13 0.0009
HMG-CoA reductase inhibitor treatment 2006 N (%) (40) 18 (25.5) 12 0.138
2016 N (%) (75) 33 (51.1) 24 0.0185
Metformin treatment 2006 N (%) 10 (22.2) 3 (6.4) 0.029
2016 N (%) 12 (26.7) 4 (8.5) 0.021
  1. HFrEF heart failure with reduced ejection fraction, HFpEF heart failure with preserved ejection fraction, ACEi/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker